ArticlePakistan journal of medical sciences2025
Impact of Eprazole Sodium combined with somatostatin on treatment efficacy and coagulation function of patients with upper gastrointestinal bleeding: A retrospective study.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative predictive value of AIMS65, Pre-endoscopic Rockall and Glasgow-Blatchford Scoring Systems in Nonvariceal Upper Gastrointestinal Bleeding.Pakistan journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the impact of eprazole sodium combined with somatostatin on the coagulation function and treatment efficacy of patients with upper gastrointestinal bleeding. Methodology: In this single-center retrospective observational study, clinical data of 105 patients with upper gastrointestinal bleeding admitted to The First People's Hospital of Yongkang (Jinhua, Zhejiang, China) from April 2023 to March 2025 were analyzed. Fifty-one patients who were treated with somatostatin and omeprazole comprised the control group. Fifty-four patients who received eprazole sodium in combination with somatostatin were included in the study group. The treatment effect, rehabilitation index (time of hemostasis, blood transfusion volume, length of hospitalization), coagulation function [fibrinogen (FIB), prothrombin time (PT), thrombin time (TT), activated partial thromboplastin time (APTT)] level, and adverse reaction rate were compared. Results: The total efficacy of the study group (96.30%) was higher than that of the control group (84.31%), while the duration of hemostasis, volume of blood transfusion, and length of hospital stay were lower (P<0.05). After treatment, the levels of FIB were higher, while PT, TT, and APTT levels decreased in both groups. The posttreatment levels of FIB in the study group were considerably higher than in the control group, while the levels of PT, TT, and APTT were significantly lower ( Conclusions: In patients with upper gastrointestinal bleeding, the combination of eprazole sodium and somatostatin can effectively shorten the hemostasis time, reduce the blood transfusion volume, improve the coagulation function, improve the overall treatment effect, promote early recovery and discharge without increasing the risk of adverse reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.